{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:38:58Z","timestamp":1773859138444,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,3]]},"DOI":"10.7759\/cureus.98368","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:33:23Z","timestamp":1764765203000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed\/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials"],"prefix":"10.7759","author":[{"given":"Asad Ali","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inshal","family":"Jawed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Sajjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Musa","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian D","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016, 43:676-81. 10.1053\/j.seminoncol.2016.11.004","journal-title":"Semin Oncol"},{"key":"ref2","unstructured":"Cancer statistics center. Accessed. February 5, 2025: https:\/\/cancerstatisticscenter.cancer.org\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01784.x","article-title":"Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era","volume":"89","author":"Dimopoulos MA","year":"2012","unstructured":"Dimopoulos MA, Kastritis E, Delimpasi S, et al.. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur J Haematol. 2012, 89:10-15. 10.1111\/j.1600-0609.2012.01784.x","journal-title":"Eur J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar SK","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, et al.. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014, 28:1122-8. 10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high-risk myeloma","volume":"2010","author":"Avet-Loiseau H","year":"2010","unstructured":"Avet-Loiseau H. Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program. 2010, 2010:489-93. 10.1182\/asheducation-2010.1.489","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold N","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, et al.. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016, 128:1735-44. 10.1182\/blood-2016-06-723007","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery DT","year":"2003","unstructured":"Avery DT, Kalled SL, Ellyard JI, et al.. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003, 112:286-97. 10.1172\/JCI18025","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann N","year":"2020","unstructured":"Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B, Kr\u00f6ger N. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020, 34:2317-32. 10.1038\/s41375-020-0930-x","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck A","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017, 16:315-37. 10.1038\/nrd.2016.268","journal-title":"Nat Rev Drug Discov"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp MS","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, et al.. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014, 32:4134-40. 10.1200\/JCO.2014.56.3247","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho SF","year":"2018","unstructured":"Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018, 9:1821. 10.3389\/fimmu.2018.01821","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339:b2700. 10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"ref13","unstructured":"International Myeloma Working Group (IMWG) uniform response criteria for multiple myeloma. Accessed. February 5, 2025: https:\/\/www.myeloma.org\/resource-library\/international-myeloma-working-group-imwg-uniform-response-criteria-multiple?...."},{"key":"ref14","unstructured":"CTCAE and adverse event reporting. (2025). Accessed. February 5, 2025: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee DW","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al.. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014, 124:188-95. 10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al.. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019, 25:625-38. 10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref17","unstructured":"Study quality assessment tools. (2021). Accessed. February 5, 2025: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp MS","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, et al.. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020, 38:775-83. 10.1200\/JCO.19.02657","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE \u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison SJ","year":"2020","unstructured":"Harrison SJ, Minnema MC, Lee HC, et al.. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE \u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM). Blood. 2020, 136:28-9. 10.1182\/blood-2020-134063","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje N","year":"2022","unstructured":"Raje N, Bahlis NJ, Costello C, et al.. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022, 140:388-90. 10.1182\/blood-2022-166494","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort A of the Magnetismm-3 study","volume":"140","author":"Bahlis NJ","year":"2022","unstructured":"Bahlis NJ, Tomasson MH, Mohty M, et al.. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort A of the Magnetismm-3 study. Blood. 2022, 140:391-3. 10.1182\/blood-2022-162440","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 Magnetismm-5 study safety lead-in cohort","volume":"140","author":"Grosicki S","year":"2022","unstructured":"Grosicki S, Mellqvist U-H, Pruchniewski \u0141, et al.. Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 Magnetismm-5 study safety lead-in cohort. Blood. 2022, 140:4407-8. 10.1182\/blood-2022-162738","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01591-9","article-title":"MM-087 early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Zonder JA","year":"2022","unstructured":"Zonder JA, Richter J, Bumma N, et al.. MM-087 early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022, 22:406-7. 10.1016\/S2152-2650(22)01591-9","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC- 1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani SZ","year":"2021","unstructured":"Usmani SZ, Garfall AL, Van De Donk NWCJ, et al.. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC- 1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021, 398:665-74. 10.1016\/S0140-6736(21)01338-6","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843628.63947.e4","article-title":"S184: evaluating teclistamab in patients with relapsed\/refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents","volume":"6","author":"Touzeau C","year":"2022","unstructured":"Touzeau C, Krishnan A, Moreau P, et al.. S184: evaluating teclistamab in patients with relapsed\/refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents. HemaSphere. 2022, 6:85-6. 10.1097\/01.HS9.0000843628.63947.e4","journal-title":"HemaSphere"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase 1B, multicohort study","volume":"140","author":"Searle E","year":"2022","unstructured":"Searle E, Quach H, Wong SW, et al.. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase 1B, multicohort study. Blood. 2022, 140:394-6. 10.1182\/blood-2022-159711","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero P","year":"2022","unstructured":"Rodr\u00edguez-Otero P, D\u2019Souza A, Reece DE, et al.. A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). J Clin Oncol. 2022, 40:8032. 10.1200\/JCO.2022.40.16_suppl.8032","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970436.12207.45","article-title":"P883: alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA \u00d7 CD3 T-cell engager, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study","volume":"7","author":"Wong SW","year":"2023","unstructured":"Wong SW, Bar N, Victoria Mateos M, et al.. P883: alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA \u00d7 CD3 T-cell engager, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Hemasphere. 2023, 7:e1220745. 10.1097\/01.HS9.0000970436.12207.45","journal-title":"Hemasphere"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza A","year":"2022","unstructured":"D'Souza A, Shah N, Rodriguez C, et al.. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2022, 40:3576-86. 10.1200\/JCO.22.01504","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel S","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, et al.. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018, 19:1641-53. 10.1016\/S1470-2045(18)30576-X","journal-title":"Lancet Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM- 2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial S","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al.. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM- 2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020, 21:207-21. 10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al.. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021, 384:705-16. 10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE- 1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja JG","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al.. Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE- 1): a phase 1b\/2 open-label study. Lancet. 2021, 398:314-24. 10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146072","article-title":"Efficacy and safety of ciltacabtagene autoleucel (Cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2","volume":"138","author":"Cohen YC","year":"2021","unstructured":"Cohen YC, Cohen AD, Delforge M, et al.. Efficacy and safety of ciltacabtagene autoleucel (Cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Blood. 2021, 138:3866. 10.1182\/blood-2021-146072","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427924-safety-and-efficacy-of-anti-b-cell-maturation-antigen-anti-bcma-bispecific-antibodies-for-relapsedrefractory-multiple-myeloma-a-systematic-review-of-clinical-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:33:25Z","timestamp":1764765205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427924-safety-and-efficacy-of-anti-b-cell-maturation-antigen-anti-bcma-bispecific-antibodies-for-relapsedrefractory-multiple-myeloma-a-systematic-review-of-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.98368","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}